In 2021, JAMA Dermatology published significant findings on skin conditions post-COVID vaccination, melanoma surveillance, atopic dermatitis treatments, and confirmed that sun protection does not harm bone health.
Patients treated with long-term intralesional corticosteroids for alopecia areata should be monitored for bone density changes and advised on osteoporosis prevention.
Dutasteride may reduce bone mineral density, but there's no increased risk of osteoporosis or fractures compared to finasteride. Users suggest resistance training to counter potential bone effects.
The conversation discusses using finasteride topically for hair loss and concerns about potential side effects like feminization and impact on muscle growth. One person shared their experience with finasteride, indicating it increased testosterone and did not prevent them from gaining muscle or strength.
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
Finasteride can cause gynecomastia due to hormonal imbalances. Management includes consulting an endocrinologist and using aromatase inhibitors like anastrozole or supplements like DIM and zinc.
Hair loss discussion mentions using estrogen mixed with growth stimulants like oral minoxidil for scalp hair growth. Idea proposed for an artificial SARM-estrogen that only affects hair without body side effects.